Background/Aims: This study aimed to validate the value of urothelial stem cell (USC) markers ΔNp63, integrin β4, CD47, and CD44v6 in predicting the prognosis of non-muscle invasive bladder cancer (NMIBC) located in different anatomic regions of bladder. Methods: The study reviewed the clinicopathologic data of 169 patients with NMIBC. Using real-time PCR and immunohistochemistry, the expression of ΔNp63, integrin β4, CD47, and CD44v6 in archived specimens of patients with NMIBC were validated. Kaplan-Meier analysis and Cox proportional hazards model were used to assess the prognostic impact of USC markers for recurrent-free survival (RFS). Results: The Real-time PCR data showed that the expression of USC markers were higher in tumors located in the trigone and posterior wall than that in other regions of bladder (P<0.05). Statistical analysis showed that high expression of ΔNp63 was correlated with tumor stage (P=0.023) and tumor size (P=0.001), that high expression of integrin β4 was correlated with tumor stage (P=0.026), tumor grade (P=0.005) and tumor size (P=0.003), and that high integrin β4, CD47, and CD44v6 expression were significantly associated with tumor recurrence (P=0.032, P=0.010, and P=0.043, respectively). Moreover, high expression of ΔNp63 and integrin β4 was correlated with poor RFS in patients with tumors located in the trigone (P=0.025 and P=0.023, respectively). High expression of integrin β4, CD47, and CD44v6 was correlated with poor RFS in patients with tumors in the posterior wall (P=0.017, P=0.033 and P=0.047, respectively). High expression of integrin β4 and CD47 was correlated with poor RFS in patients with tumors in the trigone/posterior wall area (P=0.002 and P=0.005, respectively). 
Introduction
Bladder cancer is the second most prevalent genitourinary malignancy with greater than 429, 000 new cases and 165, 000 deaths per year worldwide [1] . In the course of their disease, up to 85% of patients present with lesion confined to the mucosa or submucosa, which is commonly termed non-muscle invasive bladder cancer (NMIBC) [2] . Even with maximum treatment, up to 45% of these patients will have tumor recurrence [3] . One major goal in treating NMIBC is to prevent the high number of recurrences [4] . Therefore, it is important to identify biomarkers to predict tumor recurrence of these patients as early as possible.
Increasing evidence suggests stem cell (SC) markers might be useful in predicting the clinical prognosis of human cancers, as many marker gene products found in stem cells are shared with the cancer stem cell (CSC) population, which is responsible for key elements of cancer progression, metastasis, and recurrence [5, 6] . In addition, SC markers have been used for the identification and isolation of putative SCs or CSCs. Urothelial stem cells (USC) have attracted considerable attention due to their possible roles in urothelium homoeostasis and tissue repair as well as their potential in tumor initiation [7, 8] . In line with this notion, recent experiments have shown striking morphological and antigenic similarities between basal and intermediate differentiated cells and the corresponding cells in urothelial carcinomas [9] . Signalling pathways involved in USC self-renewing and cell differentiation are also implicated in the malignant transformation of urothelial carcinomas [10, 11] . Therefore, understanding the expression and properties of specific USC markers may help improving our knowledge of urothelial biology and tumorigenesis.
Several biomarkers including ΔNp63, integrin β4, CD47, and CD44v6 have been reported as putative USC markers. ΔNp63, the N-terminal truncated isoform of p63, is involved in normal development of several epithelial tissues, including the bladder and prostate glands, and ΔNp63-positive cells represent the stem/progenitor cells of bladder epithelium during development [12] . ΔNp63 isoform also account for p63 protein expression in normal and neoplastic urothelial tissue. In low-grade papillary bladder cancer, p63 expression was mainly in the basal layer as well as in normal bladder epithelium, whereas it was frequently undetectable in high-grade invasive cancer cells. Strikingly, impaired ΔNp63 expression correlated with a poor prognosis of invasive urothelial neoplasms [13] . Kurzrock et al. identified label-retaining cells (LRCs) in the bladder epithelium using a BrdU pulse-chase assay, and found that the urothelial LRCs population had a uniquely high expression of integrin β4 [14] , whose expression was significantly related to tumor differentiation and depth of invasion in bladder carcinomas [15] . Chan et al. demonstrated that CD47 is highly expressed in bladder tumor-initiating cells, and could inhibit macrophage engulfment of bladder cancer cells in vitro [16] . In addition, the tumorigenic potential of CD44 + cancer cells in immunocompromised mice was significantly enhanced compared with that in CD44 − cells [16] . In vitro colony-forming assay also showed that the CD44 splice variant CD44v6 was enriched in bladder cancer stem cell subpopulations [17] .
Investigation of the morphological structure and mRNA levels in different regions of bladder has revealed that the molecular organization of the urothelium was different in each bladder region [18, 19] . Moreover, high concentration of urothelial progenitor cells was found to be present in the bladder trigone [20] , further implying that the processes underlying stem cell mediated bladder tumorigenesis and tumor development may vary in different topographic regions of the bladder. Therefore, we hypothesised that the significance of USC markers may not be universal amongst NMIBC but may be region specific. In order to assess the prognostic role of USC markers in NMIBC, we divided the tumors into 6 subgroups according to their anatomic region (trigone, posterior wall (PW), right wall (RW), left wall 
Materials and Methods

Patients and tissue specimens
This study collected data from a total of 169 NMIBC patients presenting with a single tumor in the bladder. None of the patients had a prior history of transitional cell carcinoma (TCC). The material was retrieved from archival paraffin-embedded surgical samples at The Second Affiliated Hospital of Nanchang University between Jan 2005 and December 2010. In addition, 60 snap-frozen bladder cancer and paired normal bladder samples (10 pairs for each region) from above patients were collected for Real-time PCR. None of the patients received preoperative chemotherapy or radiation therapy. All patients received transurethral resection of bladder cancer and postoperative instillation of intravesical chemotherapy (50mg pirarubicin was given once a week for 8 weeks followed by once a month for 10 times), according to the national guidelines. For the use of these clinical materials for scientific purposes, prior written consent was obtained from all patients and this study was approved by the Research Ethics Committee of The Second Affiliated Hospital of Nanchang University.
RNA Extraction and Real-time PCR
Total RNA from bladder cancer and paired normal bladder tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions [21] . The extracted RNA was pretreated with RNase-free DNase, and 2μg RNA from each sample was used for cDNA synthesis with random hexamers. Real-time PCR was performed using the Applied Biosystems 7500 Sequence Detection system with a SYBR Green Real-Time PCR Master Mix (Invitrogen, Carlsbad, California, USA). The primers used are as follows: ΔNp63, forward, 5'-GAAAACAATGCCCAGACTCAATTT-3', reverse, 5'-TCTGCGCGTGGTCTGTGTTAT-3'; integrin β4, forward, 5'-CCTCATGGATGGTCTAACCC-3′ , reverse, 5'-TGAGTGCTGAGAGAGCCACT-3'; CD47, forward, 5'-GGCAATGACGAAGGAGGTTA-3', reverse, 5'-ATCCGGTGGTATGGATGAGA-3'; CD44v6, forward, 5'-TTACAGCCTCAGCAGAGCAC-3', reverse, 5'-TGACCTAAGACGGAGGGAGG-3'; GAPDH, forward, 5'-AGAAGGCTGGGCTCATTTG-3', reverse, 5'-AGGGGCCATCCACAGTCTTC-3'. The expression level of USC markers mRNA was calculated using a ratio of USC markers mRNA to GAPDH mRNA.
Immunohistochemistry
In brief, paraffin-embedded specimens were cut into 4μm sections and baked at 65°C for 30 minutes. The sections were then deparaffinized in xylene and rehydrated. The sections were treated with 3% hydrogen peroxide in methanol to quench the endogenous peroxidase activity, followed by incubation overnight with monoclonal rabbit antibody against ΔNp63 (BioLogo, Kronshagen, Germany; 1:100), monoclonal mouse antibody against integrin β4 (Abcam, Cambridge, USA; 1:250), polyclonal rabbit antibody against CD47 (Abcam, Cambridge, USA; 1:200), and monoclonal rabbit antibody against CD44v6 (Abcam, Cambridge, USA; 1:150). Human cervical carcinoma tissues was used as positive control for integrin β4, and CD44v6 staining, while human prostate tissues was used as positive control for ΔNp63 and CD47. Negative controls were obtained by excluding the primary antibody. After washing, the sections were incubated with prediluted secondary antibody (Abcam, Cambridge, USA), followed by further incubation with 3, 3-diaminobenzidine tetrahydrochloride (DAB).
IHC Scoring
The degree of immunostaining was evaluated by two independent observers who were blind to the clinical data of the patients. The scores were determined by combining the proportion of positively stained tumor cells and the intensity of staining [22] . Intensity of stained cells was graded semi-quantitatively into four levels: 0 (no staining); 1 (weak staining = light yellow); 2 (moderate staining = yellow brown) and 3 (strong staining = brown); and the proportion was scored as: 0, negative; 1, 10% or less; 2, 11% to 50%; 3, 51% to 80%; or 4, 80% or more positive cells. Intensity and fraction of positive cell scores were multiplied for each marker and thus the scoring system was defined as low expression for scores of 0-4, and as high expression for scores of > 4. Two or more coexpression of USCs was regarded as coexpression of USCs.
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Follow-up and Statistical analysis
All statistical analyses were carried out using the SPSS 16.0 statistical software package (SPSS Inc, Chicago, USA). Follow-up was available for all patients with a median time of 36 months (mean time = 33.1 months). All patients completed a 5-year follow-up after surgical resection. The recurrence-free survival was calculated as the time from the date of the primary surgery to the date of first recurrence or until last follow-up (8 patients were lost to follow-up). Comparisons between USC expression and tumor locations for statistical significance were carried out with Student t test. The Recurrence-free survival (RFS) was calculated as the time from the date of primary surgery to the date of first recurrence. Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. The significance of various variables for survival was analyzed by the Cox proportional hazards model in the multivariate analysis. P < 0.05 in all cases was considered statistically significant.
Results
Patient characteristics and tumor location
The median follow-up period of the patients was 33.1 months (range 1-60 months), 84 patients had postoperative recurrent disease. The primary tumor site was in the trigone of bladder in 38 (22.5%) of the patients, in the posterior wall in 50 (29.6%) of the patients, in the left wall in 36 (21.3%) of the patients, in the right wall in 26 (15.4%) of the patients, in the anterior wall in 11 (6.5%) of the patients, and in the dome in 8 (4.7%0 of the patients.
Patterns of expression
ΔNp63 immunoreactivity was nuclear and high expression was observed in 129 cases (76.3%). Integrin β4 immunoreactivity was both membranous and cytoplasmic and high expression was observed in 61 cases (36.1%). CD47 immunoreactivity was both membranous and cytoplasmic and high expression was observed in 118 cases (69.8%). CD44v6 immunoreactivity was both membranous and cytoplasmic and was observed in 64 cases (37.9%).
The representative immunostaining of ΔNp63, integrin β4, CD47 and CD44v6 were shown in Fig. 1 . Moreover, we investigated the mRNA expression of USC markers in cancers located in (Table  1) . Furthermore, Integrin β4, CD47, and CD44v6 expression were significantly associated with cancer recurrence (P=0.032, P=0.010, and P=0.043, respectively), while ΔNp63 expression was not correlated with tumor recurrence (Table 2) .
Associations between USC markers expression and clinical prognosis
To examine the prognostic role of USC markers in bladder cancer, we evaluated the correlation of ΔNp63, integrin β4, CD47, and CD44v6 expression with the RFS in NMIBC patients. The results showed that high expression of integrin β4, CD47, and CD44v6 (P=0.016, P=0.041, and P=0.043, respectively, Fig. 3A-3D) were correlated with poor RFS in 169 NMIBC patients. Moreover, patients with coexpression of USCs had significantly shorter RFS in compared with that without USCs coexpression (P=0.02, Fig. 3E) . Notably, high expression of ΔNp63 and integrin β4 was correlated with poor RFS in NMIBC patients with tumors located in the trigone (P=0.025 and P=0.023, respectively, Fig. 4A ). Additionally, high expression of integrin β4, CD47, and CD44v6 was correlated with poor RFS in NMIBC patients with tumors located in the posterior wall (P=0.017, P=0.033 and P=0.047, respectively, Fig.  4B ). When combining the trigone and posterior wall areas, patients with tumors exhibiting higher integrin β4 and CD47 expression had a significantly shorter RFS (P=0.002 and P=0.005, respectively, Fig. 4C ). Multivariate analysis indicated that high integrin β4 and CD47 expression were independent prognostic factors of NMIBC patient's RFS (P=0.003 and P=0.010, respectively, Table 3 ), while high ΔNp63, integrin β4, and CD47 expression could be used as independent prognostic factors for trigone/posterior wall subgroup patients (P=0.002, P<0.001, and P<0.001, respectively, Table 3 ). 
: USC Markers Predict RFS of NMIBC in Different Areas
Discussion
USC markers have attracted considerable attention in tumor diagnostic and prognostic implications. Understanding the tumor characteristics according to the position of the primary tumor in the bladder may help improving our knowledge of urothelial tumor biology and the design of treatment protocol. In the present work, we provide the first link between the expression of four USC markers (ΔNp63, integrin β4, CD47, and CD44v6) and the clinical characteristics of bladder cancer patients. We also investigate the expression of USC markers in relation to the tumor recurrence in terms of the different regions of bladder.
It has been suggested that epithelial stem cells are usually clustered in association with a specialized niche [23] . For example, hair follicle stem cells has been found to locate in the bulge region of the follicle , and corneal epithelial stem cells are proposed to be located in the basal layer of the limbal epithelium [23] . Likewise, several studies support the existence of different urothelial lineages governed by their own population of stem cells in the bladder. First, it is generally known that the bladder epithelium is derived from endoderm, while bladder trigone urothelium is mesoderm or endoderm derived has been controversial [24] . Recent evidence showed that trigone derives mostly from the rest of the bladder with a more minor contribution from the ureter, or Wolffian ducts or a combination of both [25] . Second, the initial occurrences of hyperplastic changes at different anatomical sites of bladder are different. For example, Wiener et al. found that the most predominant subsites of Brunn's nests and cystitis cystica in bladder are trigone (79.8% and 73.3%), bladder neck (68.5% and 53.3%), and posterior wall (65.2% and 30%) [26] . Similarily, more than 80% of nonkeratinizing squamous metaplasias were discovered in bladder neck and trigone [27] . Third, the initial occurrences of TCC in different bladder subsites were compared as well. Carcinoma of lateral walls and posterior wall are the most frequent sites of origin of TCC, accounting for 37.8% and 17.6%, respectively [28] . These studies suggested that these distinct populations of urothelial stem cells at different anatomical sites may play roles in giving rise to different population of urothelial tumors. Our study showed that tumors in the trigone and posterior wall exhibited higher levels of USC markers, indicating that a high concentration of stem cells may be involved in the tumorigenesis of TCC in bladder trigone and posterior wall.
Although SC markers have been used to predict the clinical survival in cancer patients, the expression of SC markers may exhibit heterogeneity between the subtypes of malignancies. For example, CD44+/CD24-appear to an independent indicator of tumor invasiveness and recurrence in breast cancer [29] , while CD44+/CD24-expression varied between breast cancer cell lines and between primary tumors, and it was not universally enriched in breast cancer stem cells [30] . Similarly, ALDH1A1 expression is strongly associated with prognosis in patients with lung adenocarcinoma, while its expression in papillary predominant adenocarcinoma was significantly higher than those of solid predominant adenocarcinoma [31] . An identical heterogeneity in a manner analogous has also been described for leukaemic stem cells [32] . Our results showed diverse USC markers expression levels in bladder cancer located in different topographic regions, indicating that heterogeneous population of bladder cancer cells may exhibit different tumorigenicity and malignancy potentials. Interestingly, we found that the prognostic significance of USC markers differs according to the location of tumors. Several assumptions are still controversial in the roles of SC markers in tumorigenesis and predicting prognosis. For example, high expression of P63 has been showed to be correlated significantly with shorter survival in gastric cancer patients [33] , while it was correlated with good prognosis in lung squamous cell carcinoma patients [34] . Likewise, integrin α6β4 has been shown to mediate an adhesion-independent tumorsuppressive effect or act as a tumor promoter in squamous cell carcinomas [35] . Together these findings underline the high extent of bladder cancer heterogeneity.
Studies addressing the prognostic significance of primary tumor location in cancers have shown conflicting results. Kroman et al. demonstrated that the clinical survival is significantly better for patients with a tumor in the upper lateral quadrant than that located elsewhere in the breast [36] . Hemminki et al. reported that tumor location of colorectal cancer was closely related to TNM classes and survival [37] . Conversely, Li et al. demonstrated that tumor location cannot be used to predict oncologic outcomes in patients with primary ureteral urothelial carcinoma [38] . Even in patients with bladder cancer, the impact of tumor location on prognosis is still controversial. Vukomanovic et al. showed that tumor location is a prognostic factor for recurrence in patients with high-grade NMIBC [39] , while study from Deng et al. indicated that tumor location may not be suitable to predict the recurrence of NMIBC [40] . Our study suggested that the prognostic significance of tumor location in NMIBC is depend on SC markers expression status. This finding may explain the diverse results reported in the literature.
Our study has 2 limitations. First, this is a retrospective study, hence there are unknown factors that may be related to clinical prognosis and were not included when we collected the data. Second, this was based on one cohort study, and additional studies on larger participant populations of more cohorts are required to confirm these preliminary findings.
Conclusion
In conclusion, we provided the first clinical evidence that USC markers could be used as prognostic markers for NMIBC patients. More importantly, we found that high expression of ΔNp63 and integrin β4 is correlated with poor prognosis in the trigone tumor group, while high expression of integrin β4, CD47, and CD44v6 predict poor prognosis for patients with cancers located in the posterior wall. The findings of our study may shed light on the prevention of bladder cancer recurrence. Patients with positive USC markers expression, especially with USCs coexpression, may need more frequent intravesical chemotherapy and cystoscopy surveillance postoperatively.
Further studies are needed to investigate the mechanism of recurrence and treatment effects of bladder cancer stratified by tumor location, which may lead to new treatment strategies for bladder cancer.
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